More positive reports from Bioshares

http://www.viralytics.com/wp-content/uploads/2015/01/Bioshares586rbpVLA.pdf

This is an interesting report insofar as it quotes, not from VLA's Board press releases, but directly from Malcolm's investor briefing.  It seems Bioshares are still bullish on the story.

A couple of quotes stood out for me;

"Viralytics has achieved startling results in mice... when combining Cavatak with an anti-PD1 compound..."  Words like startling appeal to me when used in science.
  
"Intravenous trials with Amgen’s T-Vec have not been conducted, possibly because T-Vec is a large envelope virus and is quickly mopped up by the innate immune system..."

"the company’s overseas institutional investors remain bemused at Viralytics’ market value of $57 million..."

I bet they're bemused.  Bemused enough to increase their stake at apparently unbelievable prices??  I wish...